Figure 5.

LV50 induce activation of caspase-3, caspase-8, and poly(ADP-ribose)-polymerase (PARP) as indicated by detection of cleaved proteins after Western blot analysis. Jurkat cells were treated with the compound, or alternatively, pretreated with CB2R antagonist SR144528 (1 μM) and then incubated with LV50 10 μM for indicated incubation times. Whole cell extracts were analyzed by antibodies specific for uncleaved caspase-3, cleaved caspase-3, uncleaved caspase-8, cleaved caspase-8, and PARP. The loading control was evaluated using anti-actin mAb. Densitometric cleaved caspase-3/uncleaved caspase-3, cleaved caspase-8/uncleaved caspase-8, and cleaved PARP/uncleaved PARP ratios are shown. The results are represented as the mean ± SD from three independent experiments. Statistical analysis indicated: *** p < 0.001 versus vehicle; §§ p < 0.01 versus pretreated with SR144528; § p < 0.05 versus pretreated with SR144528.